Saporito Andrea, La Regina Davide, Hofmann Axel, Ruinelli Lorenzo, Merler Alessandro, Mongelli Francesco, Trentino Kevin M, Ferrari Paolo
Faculty of Biomedical Sciences, University of Italian Switzerland, Lugano, Switzerland.
Division of Anesthesiology, Bellinzona e Valli Regional Hospital, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
Front Med (Lausanne). 2022 Aug 30;9:956128. doi: 10.3389/fmed.2022.956128. eCollection 2022.
Red blood cell (RBC) transfusions in surgical patients are associated with increased morbidity a hospital stay. However, little is known about how clinical and economic outcomes differ between appropriately and inappropriately transfused patients. We hypothesized that inappropriate RBC transfusions in elective surgical patients would significantly increase hospital cost. The aim of this study was to quantify the economic burden associated with inappropriate RBC transfusions.
We retrospectively included all adult patients admitted for elective non-cardiac surgery between January 2014 and March 2020. Patients were divided into three groups (not transfused, appropriately transfused and inappropriately transfused). The primary outcome was the excess in hospital cost in patients inappropriately transfused compared to non-transfused patients. Costs were calculated using a bottom-up approach and involving cost calculation on a granular level. According to international guidelines, transfusions were considered appropriate if administered with an ASA score of 1-2 and the last hemoglobin level measured before transfusion < 70 g/L, or with an ASA score ≥ 3 and the last hemoglobin level < 80 g/L. Cases where RBC transfusions were deemed necessary regardless of the Hb levels were reviewed by the patient blood management (PBM) board and classified accordingly. Secondary outcomes included total transfusion rate, transfusion index, and length of hospital stay. Statistical analysis was carried out by multivariable regression models.
During the study period there were 54,922 consecutive surgical admissions, of these 1,997 received an RBC transfusion, with 1,125 considered inappropriate. The adjusted cost of each inappropriate RBC transfusions was estimated in United States dollars (USD) 9,779 (95% CI, 9,358 - 10,199; < 0.001) and totaled USD 11,001,410 in our series. Inappropriately transfused patients stayed 1.6 times (95% CI, 1.5-1.6; < 0.001) longer in hospital (10.6 days vs. 6.7 days) than non-transfused patients and a mean 2.35 RBC units per patient were administered.
Inappropriate RBC transfusions in elective surgical patients seem to be common and may represent a significant economic burden. In our experience, inappropriate transfusions significantly increased hospital costs by an average of USD 9,779 compared to non-transfused patients. Through specific PBM policy, hospitals may improve cost-effectiveness of their elective surgical activity by lowering inappropriate transfusions.
外科手术患者输注红细胞(RBC)与发病率增加及住院时间延长有关。然而,对于输注恰当与不恰当的患者之间临床和经济结局如何不同,人们知之甚少。我们假设择期手术患者不恰当的RBC输注会显著增加住院费用。本研究的目的是量化与不恰当RBC输注相关的经济负担。
我们回顾性纳入了2014年1月至2020年3月期间因择期非心脏手术入院的所有成年患者。患者被分为三组(未输血、输注恰当、输注不恰当)。主要结局是与未输血患者相比,输注不恰当患者的住院费用超支情况。费用采用自下而上的方法计算,涉及在细粒度水平上的成本计算。根据国际指南,如果在ASA评分1-2且输血前最后一次测量的血红蛋白水平<70 g/L时进行输血,或ASA评分≥3且最后一次血红蛋白水平<80 g/L时进行输血,则认为输血是恰当的。无论血红蛋白水平如何,被认为有必要进行RBC输血的病例由患者血液管理(PBM)委员会进行审查并相应分类。次要结局包括总输血率、输血指数和住院时间。采用多变量回归模型进行统计分析。
在研究期间,共有54922例连续的手术入院患者,其中1997例接受了RBC输血,1125例被认为是不恰当的。每例不恰当RBC输血的调整后成本估计为9779美元(95%CI,9358-10199;<0.001),在我们的系列中总计11001410美元。输注不恰当的患者住院时间(10.6天对6.7天)比未输血患者长1.6倍(95%CI,1.5-1.6;<0.001),且每名患者平均输注2.35个RBC单位。
择期手术患者不恰当的RBC输注似乎很常见,可能代表着重大的经济负担。根据我们的经验,与未输血患者相比,不恰当输血平均使住院费用显著增加9779美元。通过特定的PBM政策,医院可以通过减少不恰当输血来提高其择期手术活动的成本效益。